Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the second quarter ended June 30, 2013.

Orexigen also announced its plan to submit a Marketing Authorization Application (MAA) for Contrave® to the European Medicines Agency (EMA) utilizing the centralized procedure. Orexigen has met with the European rapporteurs to discuss the filing strategy of the MAA. Both were supportive of the company's plan to submit the application in advance of the Light Study interim analysis and to have cardiovascular outcomes data from the Light Study available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.

"We are pleased with recent progress toward the Contrave MAA for Europe. From our interactions with multiple regulatory authorities in Europe, including with the assigned rapporteur and co-rapporteur, we believe European regulators recognize the need for new obesity therapeutics and support our plans for submission of the Contrave MAA," said Michael Narachi, Chief Executive Officer of Orexigen.

Narachi continued: "We remain focused on diligent execution of the Light Study, submission of the MAA within the next few months and resubmission of the NDA shortly after the interim analysis, which we continue to expect in the remaining months of 2013."

For the three months ended June 30, 2013, Orexigen reported a net loss of $18.2 million, or $0.19 per share, as compared to a net loss of $16.7 million, or $0.25 per share, for the second quarter of 2012.

Total operating expenses for the second quarter of 2013 were $19.1 million compared to $17.6 million for the second quarter of 2012. This overall increase in operating expenses reflects an increase in general and admini
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... OSAKA, Japan , ... -- ... confirmed,   including Core ... EPS    ... Underlying revenue +6.1% year-to-year (reported revenue growing +8.5% to 446.3 billion yen) ...
(Date:7/29/2015)... , July 29, 2015  Unilife Corporation ("Unilife" or ... a developer, manufacturer and supplier of injectable drug delivery ... strategy that provides the Company with flexibility and control ... Unilife has signed an equity purchase agreement for up ... ("LPC"), a Chicago -based institutional investor, ...
(Date:7/29/2015)... COPENHAGEN, Denmark , July 29, 2015  Ascendis ... biotechnology company that applies its innovative TransCon technology to ... will host a conference call on July 30, 2015, ... results from a Phase 2 pediatric study of once-weekly ... release of the top-line results before the market opens ...
Breaking Medicine Technology:Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2
... STXS ) today announced that executive management will ... Tuesday, September 28, 2010 at 8:30 a.m. ET in New ... of the Company,s business strategy and recent corporate developments. ... A live audio and slides webcast of Stereotaxis, presentation may ...
... Instrumentation Laboratory (IL), today announced it will host the ... 2010 at the Grand Hyatt Nusa Dua, in Bali, Indonesia. ... local time.  The forum will focus on the latest clinical ... practicing in the Asia Pacific region are welcome to attend. ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:7/30/2015)... ... 30, 2015 , ... Ross A. Clevens, MD, FACS has been ... of Plastic Surgery. This is Dr. Clevens’ second appointment by the prestigious school. ... developing a strong presence and a valuable mentoring program for medical students. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences ... Special Olympics World Games, the largest sports and humanitarian event in the world this ... , The World Games, held July 25 through August 2, 2015, benefited from the ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... 30, 2015 , ... Political unrest is the number one ... new survey by leading international insurance provider Clements Worldwide. The "Clements Worldwide Risk ... the largest sources of financial losses among respondents. , Twenty-eight percent of top ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3
... blood sugar namely blindness, malfunction of the kidneys are known. ... have now come out with astonishing details that a raise ... than 100 adults with type 1 diabetes hwo had four ... mouth, having a sweet taste in their mouth and needing ...
... the globe as 95% of the AIDS victims dwell ... Special Session on HIV/AIDS, physicians demanded to bring down ... the AIDS victims in developing countries. ,Dr. Anne-Valerie ... as Medicines Sans Frontieres, or MSF), MSF provides healthcare ...
... Heart Association's 41st Annual Conference on Cardiovascular Disease Epidemiology ... new cousin counterpart to heart disease-Asthma. It is found ... ,Carlos Iribarren, MD, MPH, PhD, of Kaiser Permanente, in ... had a risk of 33% towards developing the heart ...
... number of psychological benefits, including fighting stress-related physical and ... found no psychological benefit from the use of ginseng. ... the sport and exercise psychology lab at the Oregon ... Engles, PhD, conducted the study and found that there ...
... the major cause of morbidity in most of the ... reluctant to take extra vitamins or iron pills, as ... were effective for improving the iron status of young ... iron deficiency in children of low-to-middle income groups. These ...
... is an inherited disease of the nervous system due ... causing symptoms such as involuntary movements and balance problems ... speech as well. ,All these days, until now, ... a mutated form of the protein 'huntingtin' which is ...
Cached Medicine News:Health News:Asthma! A new warning for heart disease 2
Reptilase-Time from Bothrops atrox...
Pefakit PiCT UFH Controls...
Pefakit PiCT LMWH Calibrators...
APTT (Ellagic Acid) - 10 ml...
Medicine Products: